Pro-atherogenic medical conditions are associated with widespread regional brain metabolite abnormalities in those with alcohol use disorder – PubMed Black Hawk Supplements

Aims: Widespread brain metabolite abnormalities in those with alcohol use disorder (AUD) were reported in numerous studies, but the effects of the pro-atherogenic conditions of hypertension, type 2 diabetes mellitus, hepatitis C seropositivity, and hyperlipidemia on metabolite levels were not considered. These conditions were associated with brain metabolite abnormalities in those without AUD. We predicted treatment-seeking individuals with AUD and pro-atherogenic conditions (Atherogenic+) demonstrate lower regional metabolite markers of neuronal viability [N-acetylaspartate (NAA)] and cell membrane turnover/synthesis [choline-containing compounds (Cho)], compared with those with AUD without pro-atherogenic conditions (Atherogenic-) and healthy controls (CON).

Methods: Atherogenic+ (n = 59) and Atherogenic- (n = 51) and CON (n = 49) completed a 1.5 T proton magnetic resonance spectroscopic imaging study. Groups were compared on NAA, Cho, total creatine, and myoinositol in cortical gray matter (GM), white matter (WM), and select subcortical regions.

Results: Atherogenic+ had lower frontal GM and temporal WM NAA than CON. Atherogenic+ showed lower parietal GM, frontal, parietal and occipital WM and lenticular nuclei NAA level than Atherogenic- and CON. Atherogenic- showed lower frontal GM and WM NAA than CON. Atherogenic+ had lower Cho level than CON in the frontal GM, parietal WM, and thalamus. Atherogenic+ showed lower frontal WM and cerebellar vermis Cho than Atherogenic- and CON.

Conclusions: Findings suggest proatherogenic conditions in those with AUD were associated with increased compromise of neuronal integrity and cell membrane turnover/synthesis. The greater metabolite abnormalities observed in Atherogenic+ may relate to increased oxidative stress-related compromise of neuronal and glial cell structure and/or impaired arterial vasoreactivity/lumen viability.

1. 1. Adinolfi LE, Zampino R, Restivo L. et al. . Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014;20:3410–7. 10.3748/wjg.v20.i13.3410. – DOI – PMC – PubMed
2. 1. Alosco ML, Gunstad J, Jerskey BA. et al. . The adverse effects of reduced cerebral perfusion on cognition and brain structure in older adults with cardiovascular disease. Brain Behav 2013;3:626–36. 10.1002/brb3.171. – DOI – PMC – PubMed
3. 1. Alosco ML, Gunstad J, Xu X. et al. . The impact of hypertension on cerebral perfusion and cortical thickness in older adults. J Am Soc Hyperten: JASH 2014;8:561–70. 10.1016/j.jash.2014.04.002. – DOI – PMC – PubMed
4. 1. Chang L, Jiang CS, Ernst T. Effects of age and sex on brain glutamate and other metabolites. Magn Reson Imaging 2009;27:142–5. 10.1016/j.mri.2008.06.002. – DOI – PMC – PubMed
5. 1. Chang L, Munsaka SM, Kraft-Terry S. et al. . Magnetic resonance spectroscopy to assess neuroInflammation and neuropathic pain. J Neuroimmune Pharmacol 2013;8:576–93. 10.1007/s11481-013-9460-x. – DOI – PMC – PubMed